Loading market dashboard
Wellgistics Health, Inc.
WGRXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Focus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progress Recent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing condition Recent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities. Recent lock-up agreement to limit shares available for sale into the market Exercise of warrants embedded in recent financing would provide funding through 2029 TAMPA, FL / ACCESS Newswire / June 1, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today provided a mid-year 2026 corporate outlook.
Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement TAMPA, FL / ACCESS Newswire / May 28, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that holders of a 1,333,930 common shares, representing a majority of the outstanding common shares of the Company, have entered into a lock-up agreement that precludes the sale of their shares into the market for at least 90 days. "This lock-up agreement, when combined with the recent restructuring of our convertible liabilities and the raising of new funding, underscores the confidence our shareholders have in management to execute against our recently-disclosed vertically-integrated growth plan outlined in the Company's recent shareholder letter," said Wellgistics Health Interim Co-CEO Gerald Commissiong.
New oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per share Automatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock The class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per share New funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors TAMPA, FL / ACCESS Newswire / May 27, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™ , today announced that it completed a financing transaction through the issuance of a new $21 million convertible debt instrument (the "New Debt") that refinances all of its outstanding convertible debt and provides $6.5 million in fresh capital (the "New Money"). The offering was oversubscribed.
1-for-50 reverse split of common shares outstanding now complete 2,513,425 common shares now outstanding A new CUSIP was issued in connection with reverse split TAMPA, FL / ACCESS Newswire / May 26, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it completed a 1-for-50 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.00001 per share (the "Common Stock"). The Reverse Split was approved by a majority of the stockholders of the Company on April 2, 2026.
This Press Release updates the information from the previous release. Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare TAMPA, FL / ACCESS Newswire / May 21, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today released a letter to shareholders expanding upon the strategy behind recently announced transactions.
Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare PHILADELPHIA, PA / ACCESS Newswire / May 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company"), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today entered into a fully binding term sheet (the "Binding Term Sheet") with Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today released a letter to shareholders expanding upon strategy behind recently announced transactions. 'Dear Fellow Shareholders, Yesterday we announced a series of transactions that, taken together, mark the most consequential strategic moment in Wellgistics Health's history.
Wellgistics Health stock falls after hours after announcing a 1-for-50 reverse stock split to maintain Nasdaq compliance.
TAMPA, FL / ACCESS Newswire / May 20, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its board of directors approved the Company's 1-for-50 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.00001 per share (the "Common Stock"). The Reverse Split was approved by a majority of the stockholders of the Company on April 2, 2026.
Datavault AI Inc. (âDatavault AIâ or the âCompanyâ) (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement, and real-world a
PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today entered into a fully binding term sheet (the “Binding Term Sheet”) with Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform Einstein.
Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results Q1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™ Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives Strategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in Pittsburgh The Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilities Company has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions TAMPA, FL / ACCESS Newswire / May 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology company, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ with licensed blockchain-enabled smart contract technology through PharmacyChain™, reported financial results for the first quarter ended March 31, 2026 and provided a second quarter 2026 business update from its President & Interim-CEO Prashant Patel, RPh. "The Company's first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth that is now beginning to reach critical mass in the second quarter," said Prashant Patel, RPh, President & Interim-CEO Prashant Patel.
TAMPA, FL / ACCESS Newswire / May 15, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026. About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey.
Highlights: According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹ Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives Participating pharmacists expected to gain access to new clinical service revenue opportunities TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.
Medicure (OTCMKTS:MCUJF - Get Free Report) and Wellgistics Health (NASDAQ: WGRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk. Profitability This table compares Medicure and Wellgistics Health's
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public. So what: If you purchased Wellgistics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.
Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs. The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Wellgistics Health Inc. (NASDAQ: WGRX) resulting from allegations that Wellgistics may have issued materially misleading business information to the investing public. So what: If you purchased Wellgistics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.
Wellgistics Health is a healthcare technology and pharmaceutical logistics company.
Wellgistics Health, Inc. (NASDAQ: WGRX - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 6,271,116 shares, a growth of 219.6% from the February 26th total of 1,962,253 shares. Based on an average daily volume of 7,921,583 shares,
Despite the positive news, investors are concerned that the acquisition may not be enough to turn around the negative revenue growth Wellgistics experienced in the last year. Revenue fell about half between the last two quarters, going from $7 million to $3 million.
TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business.
TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.
TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders. The prescription drug and broader healthcare landscapes in the United States are rapidly changing.
Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company1 TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has.
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs.
